In Part I of this review, melatonin's effects in general medicine were discussed, along with a discussion of safety. Part II of this review focuses on the uses of melatonin in oncology. This includes a discussion of the uses of melatonin in breast cancer patients, including those receiving surgery, radiation, chemotherapy, and endocrine therapy. The uses of melatonin alongside additional conventional therapies for people with other types of cancer are also discussed. Studies utilizing melatonin for people with metastatic disease are also reviewed. Lastly, a brief discussion of melatonin alongside immunotherapy is included.
Get full access to this article
View all access options for this article.
References
1.
MahmoodD. Pleiotropic effects of melatonin. Drug Res (Stuttg), 2019; 69:65–74.
TalibWH, AlsayedAR, AbuawadA, et al.Melatonin in cancer treatment: Current knowledge and future opportunities. Molecules, 2021; 26:2506.
4.
TaroccoA, CarocciaN, MorcianoG, et al.Melatonin as a master regulator of cell death and inflammation: Molecular mechanisms and clinical implications for newborn care. Cell Death Dis, 2019; 10:1–12.
5.
CosS, GonzálezA, Martínez-CampaC, et al.Estrogen-signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev, 2006; 30:118–128.
6.
JinY, ChoiYJ, HeoK, et al.Melatonin as an oncostatic molecule based on its anti-aromatase role in breast cancer. Int J Mol Sci, 2021; 22:1–13.
7.
De Arruda VeigaEC, SimõesR, ValentiVE, et al.Repercussions of melatonin on the risk of breast cancer: A systematic review and meta-analysis. Rev Assoc Med Bras, 2019; 65:699–705.
8.
HansenMV, AndersenLT, MadsenMT, et al.Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat, 2014; 145:683–695.
9.
MadsenMT, HansenMV, AndersenLT, et al.Effect of melatonin on sleep in the perioperative period after breast cancer surgery: A randomized, double-blind, placebo-controlled trial. J Clin Sleep Med, 2016; 12:225–233.
10.
HansenMV, MadsenMT, AndersenLT, et al.Effect of melatonin on cognitive function and sleep in relation to breast cancer surgery: A randomized, double-blind, placebo-controlled trial. Int J Breast Cancer, 2014; 2014:1–9.
11.
Sedighi PashakiA, MohammadianK, AfsharS, et al.A randomized, controlled, parallel-group, trial on the effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments. Integr Cancer Ther, 2021; 20:1534735420988343.
12.
PalmerACS, ZorteaM, SouzaA, et al.Clinical impact of melatonin on breast cancer patients undergoing chemotherapy; effects on cognition, sleep and depressive symptoms: A randomized, double-blind, placebo-controlled trial. PLoS One, 2020; 15:e0231379.
13.
Ben-DavidM, ElkayamR, GelernterI, et al.Melatonin for prevention of breast radiation dermatitis: A phase II, prospective, double-blind randomized trial. Isr Med Assoc J, 2016; 18:188–192.
14.
ChenWY, Giobbie-HurderA, GantmanK, et al.A randomized, placebo-controlled trial of melatonin on breast cancer survivors: Impact on sleep, mood, and hot flashes. Breast Cancer Res Treat, 2014; 145:381–388.
15.
InnominatoPF, LimAS, PaleshO, et al.The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Support Care Cancer, 2016; 24:1097–1105.
16.
LissoniP, BarniS, MeregalliS, et al.Modulation of cancer endocrine therapy by melatonin: A phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer, 1995; 71:854–856.
17.
ElsabaghHH, MoussaE, MahmoudSA, et al.Efficacy of melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Dis, 2020; 26:566–572.
18.
OnsengK, JohnsNP, KhuayjarernpanishkT, et al.Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med, 2017; 23:957–963.
19.
LissoniP, MeregalliS, NosettoL, et al.Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology, 1996; 53:43–46.
20.
YanJ, ShenF, WangK, et al.Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: A prospective study. Hepatobiliary Pancreat Dis Int, 2002; 1:183–186.
21.
LissoniP, BrivioO, BrivioF, et al.Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. J Pineal Res, 1996; 21:239–242.
22.
LissoniP, RovelliF, MaluganiF, et al.Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett, 2001; 22:45–47.
23.
LissoniP, BarniS, CattaneoG, et al.Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology, 1991; 48:448–450.
24.
NeriB, de LeonardisV, GemelliM, et al.Melatonin as biological response modifier in cancer patients. Anticancer Res, 1998; 18:1329–1332.
25.
GrutschJ, HrusheskyW, LisC, et al.Daily evening melatonin prolongs survival among patients with advanced non-small-cell lung cancer. Biol Rhythm Res, 2021; 1–15.
26.
LissoniP, ChilelliM, VillaS, et al.Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: A randomized trial. J Pineal Res, 2003; 35:12–25.
27.
SeelyD, WuP, FritzH, et al.Melatonin as adjuvant cancer care with and without chemotherapy: A systematic review and meta-analysis of randomized trials. Integr Cancer Ther, 2012; 11:293–303.
28.
WangY, JinB, AiF, et al.The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: A meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol, 2012; 69:1213–1220.
29.
HaslamA, PrasadV. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open, 2019; 2:e192535.
30.
TassoniS. Modulation of immune and anti-tumor effects of cancer immunotherapy with anti-Pd-1 monoclonal antibodies by the pineal hormone melatonin: Preliminary clinical results. J Immunol Allergy, 2020; 1:1–6.
